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 7 
Abstract 8 
The brain hosts a vast and diverse repertoire of neuropeptides, a class of signaling molecules 9 
often described as neurotransmitters. Here I argue that this description entails a catalogue of 10 
misperceptions, misperceptions that feed into a narrative in which information processing in 11 
the brain can be understood only through mapping neuronal connectivity and by studying the 12 
transmission of electrically conducted signals through chemical synapses. I argue that 13 
neuropeptide signaling in the brain involves primarily autocrine, paracrine and 14 
neurohormonal mechanisms that do not depend on synaptic connectivity, and that it is not 15 
solely dependent on electrical activity but on mechanisms analogous to secretion from 16 
classical endocrine cells. As in classical endocrine systems, to understand the role of 17 
neuropeptides in the brain we must understand not only how their release is regulated, but 18 
also how their synthesis is regulated and how the sensitivity of their targets is regulated. We 19 
must understand also the full diversity of effects of neuropeptides on those targets, including 20 
their effects on gene expression. 21 
 22 
  23 
Introduction 24 
Endocrinology is the study of hormones, secreted by endocrine glands in one part of 25 
the body, that travel in the blood and have prolonged effects on other parts of the body - 26 
effects that are determined by tissue-specific expression of their receptors. By contrast, 27 
neuroscience is the study of the brain, and particularly of neurones that release 28 
neurotransmitters at synapses with effects tightly localised in space and time, constrained by 29 
mechanisms of rapid reuptake and degradation. The schism between neuroscience and 30 
endocrinology, between interests above the neck and below it, is reflected in differences in 31 
dominant technological and methodological approaches and in different theoretical visions. 32 
Neuroscience has been dominated by electrophysiology and the study of information 33 
transmission by mapping neuroanatomical connectivity and by studying the spiking activity 34 
of neurones and its consequences for cognition and behaviour; endocrinology by the 35 
measurement of hormones and the analysis of the mechanisms by which they are produced 36 
and the signaling mechanisms by which they act. 37 
 Between these two, dangling below the brain and bathed in blood, is the pituitary 38 
gland, and dangling between neuroscience and endocrinology is neuroendocrinology, born of 39 
Geoffrey Harris’ insights in the 1950’s. 40 
 41 
The birth of neuroendocrinology 42 
In the late 1950’s it was “well established” that in man and other animals that 43 
ovulated spontaneously, ovulation is controlled by the pituitary [1]. It was commonly 44 
believed that, in each ovarian cycle, increasing levels of estrogen triggered the secretion of 45 
gonadotropin hormones by direct actions on the pituitary. This “fact” was challenged by 46 
Harris, who argued that, in inducing ovulation, estrogen acted not on the pituitary but on the 47 
brain, where its actions resulted in the release from the hypothalamus of a substance that was 48 
carried by blood vessels to the pituitary [2]. In Harris’ theory, this was one of several 49 
‘releasing factors’, each of which regulated a different pituitary hormone. 50 
Harris and his co-workers showed that portal blood vessels in the median eminence at 51 
the base of the hypothalamus fed into a “vascular plexus” that filled the anterior pituitary, and 52 
that the direction of flow in these vessels was from the brain, not to it. He then noted that, 53 
from earlier work, transplanting the anterior pituitary gland to a different part of the body led 54 
to an irreversible loss of function and atrophy of the target tissues on which pituitary 55 
hormones were known to act. But if the anterior pituitary was removed from its normal place 56 
in the sella turcica and then replaced there or in an adjacent site, normal function often 57 
returned. Harris hypothesised that, in these cases, the portal vessels had regenerated, 58 
renewing the vascular communication between brain and pituitary [2]. 59 
To test this, Harris and Jacobsohn [3] removed the pituitary from female rats. They 60 
then grafted pituitary tissue from new-born young into the subarachnoid space below the 61 
brain, either immediately below the cut portal vessels, or to one side below the temporal lobe. 62 
Ovarian cycles returned in all rats with transplants below the cut portal vessels, but when the 63 
transplants were below the temporal lobe, the ovaries and reproductive tracts atrophied and 64 
ovarian cycles ceased. In both cases, the transplants were re-vascularised – in the first case by 65 
portal vessels, in the second case by blood vessels of a different part of the brain. 66 
But the path to acceptance of Harris’ theory was not yet clear. His theory blurred the 67 
conventionally accepted distinction between neurones and endocrine cells, and it postulated 68 
the existence of “releasing factors” whose identification seemed beyond experimental reach. 69 
It engaged the opposition of Sir Solly Zuckerman [4]. Zuckerman, as described by Lord 70 
Dainton, “…was unique. No scientist this century can match him in the timespan and weight 71 
of his influence on governments in peace or war” [5]. 72 
Zuckerman, who had founded his career on studies of the menstrual cycle in primates, 73 
recognised that Harris’ theory would be disproved if any animal could be shown to have 74 
ovulated in the absence of portal vessels. In sixteen female ferrets, Thomson and Zuckerman 75 
[6] cut the neural stalk, and their case rested on results from two of them, two that had come 76 
into heat in response to artificial light even though, from their histological evidence, all 77 
connections between brain and pituitary had been eliminated. 78 
But Harris suspected that the portal blood vessels had regenerated in these ferrets, so 79 
he and Donovan [7] set about their own experiments on ferrets. In their key experiments, 80 
after cutting the stalk, they inserted a paper plate between the stalk and the pituitary to 81 
prevent revascularisation of the pituitary by the portal vessels. In all ferrets where the plate 82 
had been inserted effectively, there was no revascularisation and no ovulation. They thus 83 
concluded that the method of stalk sectioning and the histological techniques used by 84 
Thomson and Zuckerman were inadequate. 85 
In 1954, Harris and Zuckerman presented their discrepant findings at a Conference in 86 
London. As later recounted by Reichlin [8], “Harris won the debate, then, and in posterity.” 87 
Harris won, not just because his evidence was more convincing, but because he could explain 88 
something that Zuckerman could not. Zuckerman’s two ferrets had come into heat in 89 
response to light – hence the pituitaries had responded to signals from the retina despite what 90 
Zuckerman had claimed to be a complete separation of the pituitary from either nerves or 91 
blood vessels. For this, Zuckerman had no credible explanation. 92 
 Zuckerman did not concede, but was still maintaining his position in 1978 93 
(Zuckerman 1978), a year after Schally and Guillemin had been awarded the Nobel Prize for 94 
their identification of some of the releasing factors that Harris had postulated. To understand 95 
Zuckerman’s resistance, we might recognise the threat that Harris’ theory posed to the 96 
community of reproductive endocrinologists among which Zuckerman was a pre-eminent 97 
authority. Harris, in placing the brain as the controller of reproduction, was shifting the 98 
responsibility for extending our understanding from endocrinologists to neuroscientists - to a 99 
different community, one already equipped with the expertise and technical methodologies 100 
that this change in focus demanded. 101 
But neuroscientists, by and large, were disinclined to take up this challenge, 102 
disparaging the hypothalamus as the remnants of the ‘lizard brain’, and they left it to a new 103 
community of neuroendocrinologists. Harris himself set about identifying the releasing factor 104 
for gonadotropins, and came close to doing so [9, 10], though ultimately the prize – and the 105 
Nobel Prize that accompanied it - went to Schally and Guillemin, whose labs were resourced 106 
at a far greater level. Nevertheless, the catalogue of Harris’ research reads like a road map for 107 
neuroendocrinology [2]. He pioneered the collection of portal blood for assays of releasing 108 
factors [11], introduced a method of remote electrical stimulation of the hypothalamus in 109 
conscious behaving animals [12], and addressed the issue of stimulus-secretion coupling in 110 
oxytocin release, a key step that became important in understanding the significance of 111 
pulsatile hormone secretion [13]. In these and many other ways, he carved out a distinctive 112 
identity for neuroendocrinology. 113 
 Barricades between endocrinologists and neuroscientists remained, and these 114 
barricades were manned by definitions. For endocrinologists, the classical definition of a 115 
‘hormone’ was that given by Starling [14]: “Each specific hormone is manufactured by a 116 
group of cells and turned into the blood, in which it travels to all parts of the body, but excites 117 
definite reactions in one or a limited number of distant organs.” For neuroscientists, on the 118 
other hand, ‘neurotransmitters’ were expected to satisfy three criteria: (i) that they were 119 
present at synapses within the presynaptic neurones, (ii) that they were released in a Ca2+-120 
dependent manner upon depolarization of those presynaptic neurones, and (iii) that they acted 121 
on specific receptors present on the postsynaptic neurone [15]. 122 
Neither endocrinologists nor neuroscientists were rigidly bound by these definitions. 123 
For endocrinologists, Starling’s definition encompassed the classical peptide and monoamine 124 
hormones well, but no complaint was made by its extension to steroid hormones, which pass 125 
cell membranes freely and can reach any targets in the body by diffusion through 126 
extravascular fluid. Nor was there objection to classing as hormones many agents that act 127 
within tissues, such as prostaglandins within the uterus, or estrogens within the ovary, or the 128 
new host of “local” hormones in many tissues. For neuroscientists, the definition of a 129 
neurotransmitter encompassed the classical neurotransmitters, packaged in synaptic vesicles 130 
whose release by exocytosis is tightly coupled to action potentials, but they came to concede 131 
that neurotransmitter release at synapses can “spill over” to act at extrasynaptic receptors [16-132 
20]. 133 
 134 
Neuropeptides 135 
Following the discovery of the releasing factors and their identification as mainly 136 
peptides, came the recognition that the class of “neuropeptides” extended far beyond the class 137 
of releasing factors. They include, on current reckoning, more than 300 different peptides 138 
expressed in various combinations in distinct subpopulations of neurones throughout the 139 
brain [21]. The brain had classically been assumed to be stocked with essentially 140 
homogeneous neurones that acquire functional specificity mainly through their patterns of 141 
hard-wired connections and which shared a common language of spiking activity. Now, it 142 
seemed to comprise a vast multitude of distinct neuronal types that spoke in multiple 143 
languages. 144 
However willing neuroscientists might have been to acknowledge peptides as an 145 
additional (though minor and supplementary) class of neurotransmitters, the facts resolutely 146 
refused to conform to this notion. As I have argued elsewhere [22], the idea that 147 
neuropeptides in the brain are neurotransmitters “is to a first approximation, a lie”, at least if 148 
we retain anything of the criteria for a neurotransmitter given above. 149 
 First to be dismissed must be the misperception that neuropeptides are released at 150 
synapses within the brain. Many neurones produce both peptides and one or more 151 
neurotransmitters, and both are packaged in vesicles, but not in the same vesicles [23]. 152 
Conventional neurotransmitters are packaged in small synaptic vesicles that are specifically 153 
localised to synapses. Peptides are packaged in large dense-cored vesicles that are typically 154 
distributed throughout the cytoplasm of a neurone, and since for most neurones the dendrites 155 
comprise about 85% of the cell volume, it is in this compartment that large dense-cored 156 
vesicles are often mainly found. Synaptic vesicles can only be released at specialised sites in 157 
the presynaptic membrane, but large dense-cored vesicles can apparently be released from the 158 
soma, dendrites, axonal varicosities and even undilated axons – the main requirement appears 159 
to be that they must be close to the plasma membrane to be releasable [24-31]. 160 
Some large dense-cored vesicles are present in synapses, though not in particular 161 
abundance, and generally not close to the synaptic release site, and whether any are ever 162 
released into the synaptic cleft is questionable. Synaptic vesicles typically contain between 163 
1,000 and 5,000 molecules of transmitter, and about one such vesicle is released when an 164 
action potential invades a synaptic ending. A typical synaptic cleft has an area of ~1 µm2, and 165 
a diameter of ~50 nm. If 1,000 molecules are released into this, they will achieve a 166 
concentration of ~0.3 mM, consistent with measures of quantal acetylcholine release at the 167 
neuromuscular junction, and amply enough to activate the low affinity receptors at which 168 
conventional neurotransmitters act [32]. However, the vesicles in which peptides are 169 
packaged carry a much larger cargo. They typically contain not only the active peptide, but 170 
the entire peptide precursor. In the case of oxytocin and vasopressin, the precursors have a 171 
molecular weight of about 23,000; each vesicle contains about 85,000 of these molecules at a 172 
density so great that the contents are in crystalloid form [33, 34], which gives these vesicles 173 
their dense-cored appearance under the electron microscope. The release of just one of these 174 
vesicles into a synaptic cleft, if confined there, would yield a peptide concentration in the 175 
high molar range. As the receptors through which peptides act have affinities in the 176 
nanomolar range, such concentrations would not merely be massively in excess for any 177 
specific receptors present, but would also act extensively at other peptide receptors present 178 
there. 179 
 Second, is the misperception that peptide release is tightly governed by electrical 180 
activity. In the rat, about 9,000 vasopressin cells project to the posterior pituitary. Each of 181 
their axons there contains about 2,000 release sites (nerve terminals and swellings), each 182 
typically containing a few hundred vesicles – about 15 billion vesicles in all, with a total 183 
content of about 2 µg of vasopressin [35]. Ludwig and Leng estimated how often these 184 
vesicles must be secreted to achieve a basal plasma concentration of vasopressin (about 1 185 
pg/ml) given a half-life of 2 min and a volume of distribution of vasopressin of 60 ml (i.e. the 186 
plasma volume and total extracellular fluid volume). These imply that about 2,500 vesicles/s 187 
are secreted in basal conditions [36]. This calculation was based on deliberately conservative 188 
assumptions and is likely to be an overestimate; the pituitary store would be sufficient to 189 
maintain this level of secretion for only about 6 days without replenishment, and for only a 190 
few hours in conditions of sustained demand, when the plasma vasopressin concentration is 191 
ten-fold higher. The actual distribution volume as inferred experimentally is about 20 ml in a 192 
rat, the plasma half-life is by many estimates, longer than 2 min, and to infer the rate of 193 
clearance from this requires modeling the exchange between plasma and extravascular fluid, 194 
as vasopressin is cleared from the plasma compartment alone by passage through the kidneys 195 
and liver [37]. More realistic assumptions imply a basal secretion rate of closer to 800 196 
vesicles/s, or about one vesicle every 10 s from each cell. After two days of dehydration, 197 
when vasopressin concentrations in the plasma are ten-fold higher, vasopressin cells fire 198 
action potentials (spikes) in long bursts at 6 to 8 spikes/s separated by silences, and each cell 199 
is secreting about 1-2 vesicles/s. In these conditions, at any single release site in the axonal 200 
endings of any one vasopressin cell, one vesicle is secreted, on average, for every 5,000 201 
spikes or so – about once every 15 min [22]. This secretion is dependent on spike activity, but 202 
the very low probability of release at any given site implies that release is a highly stochastic 203 
process. 204 
 Third is the misconception that peptide release in the brain is governed only by 205 
electrical activity. Most of the vesicles that oxytocin cells hold within the brain are located in 206 
their long and voluminous dendrites. These are not normally releasable by electrical activity, 207 
but are constrained by an intracellular scaffold of filamentous actin to be far from the 208 
voltage-gated channels which are activated by the spikes that these dendrites conduct. 209 
However, some peptides trigger oxytocin release from these dendrites by mobilising 210 
intracellular Ca2+ stores from the rough endoplasmic reticulum that permeates the dendrites 211 
[31, 38, 39]– and some, like α-MSH, stimulate dendritic release even while inhibiting spiking 212 
activity [40]. This is not to say that spike activity never releases dendritic oxytocin – some 213 
peptide signals can trigger a reorganisation of the filamentous actin to deliver vesicles close 214 
to the plasma membrane where they can be released in response to voltage-gated Ca2+ entry 215 
[41]. This mechanism –“priming” – underlies a change in the functional connectivity between 216 
oxytocin neurones, through autocrine and paracrine actions that bind the functional activity of 217 
oxytocin cells together. In lactation, this supports their ability to generate synchronous bursts 218 
in response to suckling, leading to the pulsatile secretion that is essential for the milk-ejection 219 
reflex [42]. 220 
 Fourth is the misconception that communication between neurones requires physical 221 
proximity between them. There is often a striking mismatch between the density of receptors 222 
in any given brain region and the density of peptide-containing fibres in that region [43, 44]. 223 
Much is often made of the sparse peptide-containing fibres that occasionally wend their way 224 
through regions of abundant receptor expression, and these may deliver a functionally 225 
important peptide signal, as in the case of oxytocin in the amygdala [45]. But even the CSF 226 
contains oxytocin concentrations that, if present in peripheral blood, would be sufficient to 227 
activate peripheral target organs. Some brain regions distant from the sites of oxytocin 228 
synthesis contain dense plexuses of oxytocin-containing fibres, and oxytocin release from 229 
these axonal varicosities will have an important ‘local’ action [46] – local to the region, rather 230 
than to directly adjacent neurones. Even then we should be cautious, for every peptide-231 
containing neurone also makes a conventional neurotransmitter, and these may often be the 232 
primary messenger of such fibres; oxytocin neurones express the vesicle glutamate 233 
transporter VGLUT2 [47], and glutamate thus appears to be a neurotransmitter used at their 234 
central synaptic projections [45, 48]. 235 
 Oxytocin and vasopressin might be exceptional in the size of their vesicles. Many 236 
dense-cored vesicles in the CNS are smaller than these, with a volume only about 1/8 that of 237 
the typical oxytocin or vasopressin-containing vesicles and a correspondingly lower expected 238 
content. Thus van den Pol [49] favours a local diffusion hypothesis, that, given the low 239 
frequency of dense core vesicles in most CNS axons and because of the hours needed to 240 
replenish released peptides by synthesis and transport from the cell body, neuropeptides 241 
released by most neurons must act relatively locally on cells near the release site. However, 242 
any one neurone has a great many potential release sites, including all its axonal varicosities, 243 
each with a very low probability of release, thus the potential targets of peptide release even 244 
from a single peptidergic neurone will be very widely scattered and widely distributed 245 
neurones will be exposed to secreted peptide in a sparse and highly stochastic fashion. When 246 
a brain region is permeated by many axons from a population of peptide-producing cells, it 247 
seems likely that such a projection will deliver a hormone-like signal to that region. How far 248 
such a signal will reach is hard to predict. 249 
A striking demonstration of remote actions of neuropeptides comes from studies of 250 
the suprachiasmatic nucleus. Lesions of this nucleus in hamsters disrupts the circadian 251 
rhythms of behaviour that persist in constant darkness. In lesioned hamsters, circadian 252 
rhythmicity can be restored by transplanting fragments of neonatal suprachiasmatic nucleus 253 
into the third ventricle – and, remarkably, can do so even if those fragments are encapsulated 254 
in a membrane that allows substances to diffuse freely across the membrane but which 255 
permits no penetration of nerve fibres from the transplant to the host tissue [50]. 256 
Fifth, to be qualified rather than dismissed, is the notion that neuropeptides are 257 
neuromodulators, in the sense that they affect neuronal excitability, thereby altering the 258 
responses of neurones to neurotransmitters. Many neuropeptides affect gene expression in 259 
their targets: canonical examples include the effects of gonadotrophin releasing hormone on 260 
pituitary expression of gonatotropins [51, 52], the effects of thyrotropin releasing hormone on 261 
thyroid stimulating hormone expression [53], and the effects of growth-hormone releasing 262 
hormone on growth hormone expression [54]. Certainly many peptides do influence neuronal 263 
excitability, but as mentioned, some can alter functional connectivity by priming peptide 264 
release from dendrites. 265 
For example, the splanchnic nerve terminals that innervate the adrenal medulla release 266 
PACAP (pituitary adenylate cyclase-activating polypeptide) and acetylcholine. Both regulate 267 
catecholamine release from chromaffin cells, but PACAP is released only at high frequencies, 268 
using secretory mechanisms different from those evoked by acetylcholine. During prolonged 269 
stress, PACAP maintains catecholamine synthesis via induction of tyrosine hydroxylase and 270 
PNMT (phenylethanolamine N-methyltransferase), and it enhances the transcription of other 271 
secreted molecules found in chromaffin cells. In the words of Smith and Eiden: “PACAP thus 272 
mediates chromaffin cell plasticity via a functional encoding of experience”[55]. 273 
Some neuropeptides regulate local blood flow [56], some, like oxytocin may regulate 274 
glial cell morphology [57], and leptin [58, 59] and CRH [60] have been proposed to modulate 275 
synaptogenesis. The predominant attention given to electrophysiological actions of 276 
neuropeptides reflects the relative ease with which these can be determined by in vitro 277 
electrophysiology, and the assumption of many neuroscientists that neuropeptides are mere 278 
adjuncts to the serious business of information transfer that is conducted by 279 
neurotransmitters. 280 
Finally, again to be qualified or at least questioned, is the notion that the roles of 281 
neuropeptides in the brain are exercised purely through activity-dependent regulation of their 282 
release. Three points should be made. (i), The level of mRNA expression for peptides in 283 
specific neuronal populations varies in different physiological states. (ii), The amount of 284 
peptide released by a given stimulus is proportional to the amount available for release, 285 
which varies with the rates of synthesis and depletion. (iii), The actions of a neuropeptide 286 
depend on the level of expression of specific receptors, which varies in different 287 
physiological conditions. These points are considered in turn below. 288 
Regulation of mRNA expression 289 
One of the earliest and most striking examples of this comes from studies of the 290 
effects of chronic stress on the parvocellular neurones in the paraventricular nucleus of the 291 
hypothalamus that regulate the secretion of ACTH. These neurones normally regulate ACTH 292 
secretion via release of corticotrophin releasing hormone (CRH), but after chronic stress their 293 
expression of CRH is diminished while that of vasopressin, in the same neurones, is markedly 294 
enhanced. Thus the peptidergic phenotype of these neurones is plastic – what were “CRH 295 
neurones” become “vasopressin neurones” with marked consequences for the regulation of 296 
the stress axis [61]. No less striking is the recent recognition of similar plasticity in the 297 
tuberoinfundibular dopamine neurones that regulate prolactin secretion. In lactation, these 298 
cease to release dopamine but instead release a peptide – leu enkephalin, and this change 299 
supports the stimulation of prolactin secretion in lactation [62]. 300 
Regulation of receptor expression 301 
The role of a peptide messenger may be exercised through activity-dependent 302 
regulation of its release, or by regulating its synthesis, or its availability for release, or the 303 
sensitivity of its targets. One classic example of the last of these is the importance of changes 304 
in oxytocin receptor expression in the uterus for parturition. In all mammals, oxytocin 305 
secretion is increased during parturition, and this acts on a uterus prepared by a massive 306 
increase in oxytocin receptor expression [63, 64]. In rats, what is secreted from pituitary is 307 
conveyed to its targets in a plasma volume of about 7.5 ml; in humans the pituitary is about 308 
40 times larger than that of a rat, and the oxytocin content is proportionately greater. 309 
However, what is secreted in a human is conveyed in a plasma volume of 3-4 l, at least 400 310 
times larger than in a rat, and the half-life of oxytocin in rat and human are similar. 311 
Accordingly circulating concentrations of oxytocin are much lower in man than in small 312 
mammals [65], and the importance of the level of receptor expression in target tissues is 313 
correspondingly greater. Indeed, the increase in the sensitivity of the human uterus to 314 
oxytocin at term pregnancy is so great that it has been questioned whether any increase in the 315 
level of oxytocin at all is involved in human parturition before the third stage of labor [64]. 316 
Among the best-known behavioural functions of peptides are those of vasopressin and 317 
oxytocin on various facets of “social” behaviour. A feature of these is how great are the 318 
species differences in these behaviours; the paradigmatic exemplars are the prairie voles, that 319 
make enduring partner bonds after mating and display biparental nurturing behaviours, and 320 
closely related species such as meadow voles which are promiscuous and asocial. These 321 
behaviours critically depend on the release within the brain of oxytocin and vasopressin, but 322 
the species differences do not apparently reflect any differences in the regulation of this 323 
release, but on differences in the sites and extent of receptor expression in the brain [66, 67]. 324 
Stimulus-secretion coupling 325 
 The amount of peptide secreted from neurones in response to electrical depolarisation 326 
depends on the pattern of stimulation [37, 55, 68, 69], on the number of vesicles available for 327 
release [70], and their precise location [24]. The nerve endings of the axons that fill the 328 
posterior pituitary contain a “readily-releasable pool” of vesicles that is refilled from reserve 329 
stores as it is depleted, and the cycle of local depletion and repletion results in complex non-330 
linearities in stimulus-secretion coupling [37, 69]. After a period of water deprivation, the 331 
gland content is severely depleted, and in these conditions electrical stimulation of the gland 332 
releases oxytocin and vasopressin in direct proportion to the gland content [70]. 333 
When a synaptic vesicle containing a conventional neurotransmitter releases its 334 
contents, there is an abundant stock of vesicles available to re-supply the releasable pool, and 335 
re-uptake mechanisms recover neurotransmitter from the extracellular fluid to refill the empty 336 
vesicle and make it available for rapid re-use. By contrast, large-dense cored vesicles cannot 337 
be re-used, they must be replaced by newly synthesised vesicles. Thus any acute activation of 338 
peptide secretion entails a cycle of depletion and repletion. Any marked increase in the rate of 339 
secretion must be compensated for by an increase in the rate of peptide synthesis and vesicle 340 
production, and the new vesicles must be transported from the cell body to the release sites – 341 
a process that can take several hours. This phenomenon will impose a temporal pattern on 342 
peptide secretion from neurones even if the signal for that secretion is unchanging. 343 
 But the availability of peptide stores is not the only factor that determines how much 344 
is secreted in response to a stimulus. As mentioned, priming of peptide stores can alter 345 
stimulus-secretion coupling in dendrites. At nerve terminals, other factors can do so. 346 
Oxytocin neurones, for example, co-express dynorphin, which acts on kappa-opioid receptors 347 
at their nerve terminals as an inhibitory feedback regulator of stimulus-secretion coupling. In 348 
pregnancy, the expression of dynorphin is upregulated, and the enhanced negative feedback 349 
contributes to a progressive accumulation of oxytocin stores in the pituitary in preparation for 350 
parturition – the gland content increases by about a third without any apparent increase in the 351 
level of oxytocin mRNA expression [63]. 352 
In β-pancreatic cells, insulin secretion in response to glucose is elicited by an increase 353 
in intracellular [Ca2+]. This “triggering” pathway depends on the suppression of KATP 354 
channels in the plasma membrane [71]. But after the first phase of insulin secretion, a 355 
metabolic amplifying pathway is engaged which depends on the initial triggering signal but is 356 
independent of KATP channels and involves cAMP signalling. This pathway enhances the 357 
sensitivity of the insulin-containing secretory vesicles to a given Ca2+ influx, and it can be 358 
engaged by peptide signals such as GLP-1 and GIP from gastrointestinal endocrine cells [72]. 359 
 360 
Three modes of action of neuropeptides 361 
When considering the actions on neurones of neuropeptides released from neurones in 362 
the brain, we can recognise three common modes of action. Neuropeptides act as 363 
autoregulators of neuronal activity, as paracrine regulators of aggregated populations of 364 
neurones, and as neurohormonal regulators of distant populations of neurones. 365 
Autocrine regulation 366 
Commonly, neurones express autoreceptors for the peptides that they release. As 367 
discussed above, in the case of oxytocin cells, activity-dependent release of dynorphin, a 368 
peptide co-packaged with oxytocin in neurosecretory vesicles but in very much lower 369 
abundance, is a negative feedback regulator of secretion from nerve terminals in the pituitary. 370 
Magnocellular vasopressin cells also express dynorphin, co-packaged in vasopressin-371 
containing vesicles. For these cells, dynorphin is again an autoregulator, but in this case of 372 
electrical activity – in vasopressin cells, sparse, activity-dependent release of dynorphin from 373 
the soma and dendrites has a critical role in sculpting the phasic pattern of electrical activity 374 
[73]. 375 
Paracrine regulation 376 
Oxytocin cells also express oxytocin receptors and vasopressin cells also express 377 
vasopressin receptors, but in both cases their functional activity is quite elusive; because the 378 
receptors are internalised after ligand binding, and because there is a high concentration of 379 
these peptides in the extracellular space around the magnocellular cells, at any given time 380 
there are normally few free receptors available for binding on the cell surface. For oxytocin 381 
cells therefore these receptors are functionally effective only when very large amounts of 382 
oxytocin are released. During lactation, dendritic oxytocin release in response to suckling 383 
binds the population of oxytocin cells together, supporting their ability to generate 384 
synchronous bursts of activity [42]. This can be considered as an example of positive 385 
feedback, but negative feedbacks can also bind a population together. In magnocellular 386 
vasopressin cells, dendritic vasopressin release is an inhibitor of neuronal activity – it acts as 387 
a “population signal” allowing each cell to be aware of the level of activity amongst the 388 
whole population, and this feedback serves to equalise the average level of activity in the 389 
population, spreading the load of activity equitably [22, 74]. 390 
Neurohormonal actions 391 
Neuropeptides in the brain are not generally scoured from the extracellular space by 392 
uptake mechanisms, and enzymatic degradation is relatively slow. They travel within the 393 
brain not by diffusion, but by the continuous flow of extracellular fluid, ending up in the CSF 394 
from which they are ultimately cleared. How much reaches the CSF varies considerably. 395 
Oxytocin and vasopressin are degraded within brain tissue by specific aminopeptidases, 396 
notably the membrane-bound enzyme PLAP [75]. Oxytocin and vasopressin are released in 397 
equimolar amounts with their respective neurophysins, which are large fragments of their 398 
precursor molecules, and the neurophysins are not enzymatically degraded within the brain. 399 
By comparing the concentrations of neurophysins in CSF with those of oxytocin and 400 
vasopressin, and given the rate of clearance from CSF, we can deduce that only about 5% of 401 
the oxytocin and vasopressin that is released within the brain actually reaches the CSF [36]. 402 
Yet their concentrations in CSF are still about ten-fold higher than the basal concentrations in 403 
plasma, and at levels that, when present in plasma, are amply sufficient to exert physiological 404 
effects. Peptide concentrations must vary considerably in different brain regions, as the result 405 
of differential degradation, the inhomogeneous flow of extracellular fluid and the variations 406 
in levels of local release. Neurohormonal signalling in brain is not homogeneous and 407 
indiscriminate. Nevertheless, such signaling reflects not a rapid and specific system of 408 
communication from neurone to neurone, but a prolonged communication between one 409 
population of cells and another – the difference between a ‘whispered secret’ and a ‘public 410 
announcement’ [36]. 411 
The potential impact of such neurohormonal signals might be glimpsed from studies 412 
in simple organisms such as Drosophila [76] and C.elegans [77]. It seems that the 413 
connectome – the wiring diagram of connectivity amongst the 302 neurones of C.elegans -414 
allows multiple potential behaviours for any given neuronal network. Which of these 415 
behaviours is expressed in a given circuit at a particular time depends on what Cornelia 416 
Bargmann called “the dark energy of the nervous system.” The C. elegans genome encodes 417 
over 200 peptides, and these, she argues, along with biogenic amines such as serotonin and 418 
dopamine, sculpt the functional connectivity between neurones – defining which of the set of 419 
latent circuits in a neuronal network is engaged at a given time [77]. 420 
 421 
Reflections 422 
The original schism between endocrinology and neuroscience was bolstered by the 423 
apparently separate embryological origins of neurones and endocrine cells. However if we 424 
look to contemporary understanding of the molecular determinants of cell fate and to 425 
comparative genomics, we see a different story [78, 79]. In Urbilateria, the marine organism 426 
proposed to be the last common ancestor of vertebrates, flies, and worms, cells that secreted a 427 
peptide ancestor of vasopressin and oxytocin combined properties that we have thought of as 428 
separate properties of endocrine cells and neurones. They used diverse signaling mechanisms, 429 
made both neurotransmitters and peptides, and had a wide range of specialized senses, 430 
linking feeding, reproduction and internal homeostasis to environmental conditions [80]. 431 
 Given the many commonalities between, for example, β-pancreatic cells or any of the 432 
pituitary cell types and neurones, it seems clear that if these cells were embedded in the brain 433 
we would not hesitate to call them neurones. Yet although information flows in both 434 
directions between the brain and endocrine glands, we still cleave to a hierarchical view in 435 
which the brain, and the higher centres of the brain in particular, are credited with particular 436 
cognitive agency, as though neurones were clever in ways that endocrine cells are not.  437 
 We can extend this argument to encompass all endocrine cells in the body. For 438 
example, the adipocytes that store our fat not only sense the environment in which they 439 
reside, they communicate bidirectionally with other endocrine cells in the pancreas [81, 82] 440 
and elsewhere, express intrinsic circadian rhythmicity[83], and are innervated by neurones 441 
[84, 85]. Through the actions of their product leptin on the brain, they not only regulate 442 
appetite by their effects on diverse populations of peptidergic neurones [86, 87], but also 443 
modulate energy expenditure [88] and food reward [89, 90]. As I have argued elsewhere, 444 
“from the perspective of an adipocyte […] the brain is just something that follows its 445 
instructions to keep it supplied with lipid.”[22]. 446 
 There are two distinct ways to conceive of intelligence. We can conceive it as the 447 
ability of a cell to sense both the external environment and its internal state combined with 448 
the ability to respond adaptively to changes in the external environment. This would be to 449 
follow the sense in which Barbara McClintock, in her Nobel Prize lecture wrote “a goal for 450 
the future would be to determine the extent of knowledge the cell has of itself and how it uses 451 
that knowledge in a “thoughtful” manner when challenged” [91]. Or we can conceive it as an 452 
emergent phenomenon, a property specific to highly complex multicellular systems that 453 
embraces the abilities to learn from past experience, to anticipate future challenges, and to 454 
select from a range of possible strategies one that will appropriately meet those challenges. 455 
Intelligence in the latter sense is embodied not in a discrete location but in the whole complex 456 
network. In neither sense can we accord neurones greater cognitive capacity than, say, 457 
adipocytes. 458 
Hierarchical metaphors of the organisation of brain and body have run their course. It 459 
is time to abandon them, and abandon too the conceit that will understand the brain through 460 
studies of neuronal connectivity and electrical activity alone. New technological advances, 461 
such as optogenetics and chemogenetics, have given unprecedented opportunities for 462 
understanding the role of electrical activity in information processing in the brain, but we are 463 
desperately in need of comparable advances in studying the functional regulation of 464 
neuropeptide release in the brain and its behavioral and physiological consequences.  465 
It is time for endocrinologists to claim the brain as one of their own, and take up the 466 
challenge of understanding the hormones of the brain. At present, we have the technical 467 
ability to measure only oxytocin and vasopressin release by radioimmunoassay in brain areas 468 
in a functional context, and only with a relatively poor spatial and temporal resolution. 469 
Nanoflow liquid chromatography-mass spectrometry offers a potentially powerful alternative 470 
to immunoassay for peptide detection because of its high sensitivity and specificity, and a 471 
recent paper has used this to measure opioid peptide release in discrete brain areas using 472 
microdialysis in fractions collected at 15-min intervals [92]. This is clearly a step forward, 473 
but temporal resolution remains a challenge. Important advances have recently been made in 474 
the ability to measure the release of some neurotransmitters with high spatial and temporal 475 
resolution through the use of genetically encoded fluorescent sensors [93, 94]. It seems 476 
possible that similar approaches may yet provide the ability to measure neuropeptide release 477 
with similar precision, but there are considerable technical barriers [95]. 478 
 While chemogenetic approaches directly target G-protein coupled receptors, 479 
optogenetic approaches have mainly been used to activate or inhibit neurones through 480 
regulation of ion channels (e.g. [45, 96]). However, optogenetic tools have also been 481 
developed to target intracellular signaling cascades [97]. Thus, both optogenetic and 482 
chemogenetic approaches should be capable of being adapted to target the non-spike 483 
dependent pathways that regulate peptide release – if the problems with measuring this 484 
release on an appropriate timescale can be overcome. 485 
 486 
Disclosures 487 
Research in the author’s lab is funded by the European Union's Seventh Framework 488 
Programme for Research, Technological Development, and Demonstration under Grant 489 
number 607310 (Nudge-It.) and by the BBSRC (BB/S000224/1). He has no interests to 490 
disclose. 491 
 492 
References 493 
1. Hisaw FL 1947 Development of the Graafian follicle and ovulation. Physiological 494 
Reviews 27 95-119. 495 
2. Harris GW 1955 Neural control of the pituitary gland. Monographs of the 496 
Physiological Society London,: E. Arnold. 298 p. 497 
3. Harris GW & Jacobsohn D 1952 Functional grafts of the anterior pituitary gland. Proc 498 
R Soc Lond B Biol Sci 139 263-276. 499 
4. Coen CW 2015 60 YEARS OF NEUROENDOCRINOLOGY: Celebrating the brain's 500 
other output-input system and the monograph that defined neuroendocrinology. 501 
Journal of Endocrinology 226 E3-6. 502 
5. Dainton 1995 Zuckerman, Solly May 30, 1904 April 1, 1993. Proceedings of the 503 
American Philosophical Society. 139 211-217. 504 
6. Thomson AP & Zuckerman S 1954 The effect of pituitary-stalk section on light-505 
induced oestrus in ferrets. Proc R Soc Lond B Biol Sci 142 437-451. 506 
7. Donovan BT & Harris GW 1956 The effect of pituitary stalk section on light-induced 507 
oestrus in the ferret. Journal of Physiology 131 102-114. 508 
8. Reichlin S 2015 60 YEARS OF NEUROENDOCRINOLOGY: MEMOIR: working 509 
in the 'Huts' with the professor: the first Maudsley years. Journal of Endocrinology 510 
226 E7-E11. 511 
9. Vogt ML 1972 Geoffrey Wingfield Harris, 1913-1971. Biographical Memoirs of 512 
Fellows of the Royal Society 18 309-329. 513 
10. Naftolin F, Harris GW & Bobrow M 1971 Effect of purified luteinizing hormone 514 
releasing factor on normal and hypogonadotrophic anosmic men. Nature 232 496-515 
497. 516 
11. Fink G 2015 60 YEARS OF NEUROENDOCRINOLOGY: MEMOIR: Harris' 517 
neuroendocrine revolution: of portal vessels and self-priming. Journal of 518 
Endocrinology 226 T13-24. 519 
12. Harris GW & Woods JW 1956 Electrical stimulation of the hypothalamus and thyroid 520 
activity. Nature 178 80-81. 521 
13. Leng G., Pineda R, Sabatier N & Ludwig M 2015, 60 YEARS OF 522 
NEUROENDOCRINOLOGY: The posterior pituitary, from Geoffrey Harris to our 523 
present understanding. Journal of Endocrinology 226 T173-185. 524 
14. Starling EH 1923 THE WISDOM OF THE BODY: The Harveian Oration, delivered 525 
before The Royal College of Physicians of London on St. Luke's Day, 1923. British 526 
Medical Journal 2 685-690. 527 
15. Purves D & Williams SM 2001 Neuroscience. 2nd ed. Sunderland, Mass.: Sinauer 528 
Associates. xviii, 681, 16, 3, 25 p. 529 
16. Hirasawa H, Contini M & Raviola E 2015 Extrasynaptic release of GABA and 530 
dopamine by retinal dopaminergic neurons. Philos Trans R Soc Lond B Biol Sci 531 
370(1672). pii: 20140186. 532 
17. Rice ME, Patel JC, & Cragg SJ 2011 Dopamine release in the basal ganglia. 533 
Neuroscience 198 112-137. 534 
18. Fuxe K, Agnati LF, Marcoli M, & Borroto-Escuela DO 2015 Volume transmission in 535 
central dopamine and noradrenaline neurons and its astroglial targets. Neurochem 536 
Research 40 2600-2614. 537 
19. Courtney NA & Ford CP 2014 The timing of dopamine- and noradrenaline-mediated 538 
transmission reflects underlying differences in the extent of spillover and pooling. 539 
Journal of Neuroscience 34 7645-7656. 540 
20. Lendvai B & Vizi ES 2008 Nonsynaptic chemical transmission through nicotinic 541 
acetylcholine receptors. Physiological Reviews 88 333-349. 542 
21. Wang Y, Wang M, Yin S, Jang R, Wang J, Xue Z & Xu T 2015 NeuroPep: a 543 
comprehensive resource of neuropeptides. Database (Oxford) 2015: bav038. 544 
22. Leng G 2018 The Heart of the Brain: The hypothalamus and its hormones. MIT Press. 545 
280. 546 
23. Torrealba F & Carrasco MA 2004 A review on electron microscopy and 547 
neurotransmitter systems. Brain Research Revoews 47 5-17. 548 
24. Morris JF & Pow DV 1991 Widespread release of peptides in the central nervous 549 
system: quantitation of tannic acid-captured exocytoses. Anat Rec 231 437-445. 550 
25. Morris JF, Christian H, Ma D & Wang H 2000 Dendritic secretion of peptides from 551 
hypothalamic magnocellular neurosecretory neurones: a local dynamic control system 552 
and its functions. Experimental Physiology 85 131S-138S. 553 
26. Pow DV & Morris JF 1989 Dendrites of hypothalamic magnocellular neurons release 554 
neurohypophysial peptides by exocytosis. Neuroscience 32 435-439. 555 
27. Del-Bel E & De-Miguel FF 2018 Extrasynaptic neurotransmission mediated by 556 
exocytosis and diffusive release of transmitter substances. Frontiers in Synaptic 557 
Neuroscience 10: 13. 558 
28. De-Miguel FF & Nicholls JG 2015 Release of chemical transmitters from cell bodies 559 
and dendrites of nerve cells. Philos Trans R Soc Lond B Biol Sci 370(1672) pii: 560 
20140181. 561 
29. Brown CH, Bains JS, Ludwig M & Stern JE 2013 Physiological regulation of 562 
magnocellular neurosecretory cell activity: integration of intrinsic, local and afferent 563 
mechanisms. Journal of Neuroendocrinology 25 678-710. 564 
30. Stern JE 2015 Neuroendocrine-autonomic integration in the paraventricular nucleus: 565 
novel roles for dendritically released neuropeptides. Journal of Neuroendocrinology 566 
27 487-497. 567 
31. Ludwig M, Apps D, Menzies J, Patel JC & Rice ME 2016 Dendritic release of 568 
neurotransmitters. Comprehensive Physiology 7 235-252. 569 
32. Steuer Costa W, Yu SC, Liewald JF, & Gottschalk A 2017 Fast cAMP Modulation of 570 
neurotransmission via neuropeptide signals and vesicle loading. Current Biology 27 571 
495-507. 572 
33. Morris JF 1976 Hormone storage in individual neurosecretory granules of the 573 
pituitary gland: A quantitative ultrastructural approach to hormone storage in the 574 
neural lobe. Journal of Endocrinology 68 209-224. 575 
34. Nordmann JJ & Morris JF 1984 Method for quantitating the molecular content of a 576 
subcellular organelle: hormone and neurophysin content of newly formed and aged 577 
neurosecretory granules. Proc Natl Acad Sci U S A 81 180-184. 578 
35. Morris JF 1976 Distribution of neurosecretory granules among the anatomical 579 
compartments of the neurosecretory processes of the pituitary gland: a quantitative 580 
ultrastructural approach to hormone storage in the neural lobe. Journal of 581 
Endocrinology 68 225-234. 582 
36. Leng G & Ludwig M 2008 Neurotransmitters and peptides: whispered secrets and 583 
public announcements. Journal of Physiology 586 5625-5632. 584 
37. Maicas-Royo J, Leng G & MacGregor DJ 2018 A predictive, quantitative model of 585 
spiking activity and stimulus-secretion coupling in oxytocin neurons. Endocrinology, 586 
2018. Jan 12. doi: 10.1210/en.2017-03068. [Epub ahead of print] 587 
38. Ludwig M & Leng G 2006 Dendritic peptide release and peptide-dependent 588 
behaviours. Nat Rev Neurosci 7 126-136. 589 
39. Ludwig M, Sabatier N, Bull PM, Landgraf R, Dayanithi G & Leng G 2002 590 
Intracellular calcium stores regulate activity-dependent neuropeptide release from 591 
dendrites. Nature 418 85-89. 592 
40. Sabatier N, Caquineau C, Dayanithi G, Bull P, Douglas AJ, Guan XM, Jiang M, Van 593 
der Ploeg L & Leng G 2003 Alpha-melanocyte-stimulating hormone stimulates 594 
oxytocin release from the dendrites of hypothalamic neurons while inhibiting 595 
oxytocin release from their terminals in the neurohypophysis. Journal of 596 
Neuroscience 23 10351-10358. 597 
41. Tobin V, Leng G & Ludwig M 2012 The involvement of actin, calcium channels and 598 
exocytosis proteins in somato-dendritic oxytocin and vasopressin release. Frontiers in 599 
Physiology 3: 261. 600 
42. Rossoni E, Feng J, Tirozzi B, Brown D, Leng G & Moos F 2008 Emergent 601 
synchronous bursting of oxytocin neuronal network. PLoS Computational Biology 602 
4(7): p. e1000123. 603 
43. Herkenham M 1987 Mismatches between neurotransmitter and receptor localizations 604 
in brain: observations and implications. Neuroscience 23 1-38. 605 
44. Zupanc GK 1996 Peptidergic transmission: from morphological correlates to 606 
functional implications. Micron 27 35-91. 607 
45. Knobloch HS, Charlet A, Hoffmann LC, Eliava M, Khrulev S, Cetin AH, Osten P, 608 
Schwarz MK, Seeburg PH, Stoop R et al. 2012 Evoked axonal oxytocin release in the 609 
central amygdala attenuates fear response. Neuron 73 553-566. 610 
46. Chini B, Verhage M & Grinevich V 2017 The action radius of oxytocin release in the 611 
mammalian CNS: From single vesicles to behavior. Trends in Pharmacological 612 
Sciences 38 982-991. 613 
47. Ponzio TA, Ni Y, Montana V, Parpura V & Hatton GI 2006 Vesicular glutamate 614 
transporter expression in supraoptic neurones suggests a glutamatergic phenotype. 615 
Journal of Neuroendocrinology 18 253-65. 616 
48. Grinevich V, Knobloch-Bollmann HS, Eliava M, Busnelli M & Chini B 2016 617 
Assembling the puzzle: pathways of oxytocin signaling in the brain. Biological 618 
Psychiatry 79 155-164. 619 
49. van den Pol AN 2012 Neuropeptide transmission in brain circuits. Neuron 76 98-115. 620 
50. Silver R., LeSauter J, Tresco PA &. Lehman MN 1996 A diffusible coupling signal 621 
from the transplanted suprachiasmatic nucleus controlling circadian locomotor 622 
rhythms. Nature 382 810-813. 623 
51. Stamatiades GA & Kaiser UB 2018 Gonadotropin regulation by pulsatile GnRH: 624 
Signaling and gene expression. Molecular and Cellular Endocrinology 463 131-141. 625 
52. Melamed P, Haj M, Yosefzon Y, Rudnizky S, Wijeweera A, Pnueli L & Kaplan A 626 
2018 Multifaceted targeting of the chromatin mediates gonadotropin-releasing 627 
hormone effects on gene expression in the gonadotrope. Frontiers in Endocrinology 628 
(Lausanne) 9: 58. 629 
53. Nakajima Y, Yamada M, Taguchi R, Shibusawa N, Ozawa A, Tomaru T, Hashimoto 630 
K, Saito T, Tsuchiya T, Okada S et al. 2012 NR4A1 (Nur77) mediates thyrotropin-631 
releasing hormone-induced stimulation of transcription of the thyrotropin beta gene: 632 
analysis of TRH knockout mice. PLoS One, 7(7): e40437. 633 
54. Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J & Cunha SR 2000 Regulation 634 
of the pituitary somatotroph cell by GHRH and its receptor. Recent Progress in 635 
Hormone Research 55 237-266. 636 
55. Smith CB & Eiden LE 2012 Is PACAP the major neurotransmitter for stress 637 
transduction at the adrenomedullary synapse? Journal of Molecular Neuroscience 48 638 
403-412. 639 
56. Owman C 1990 Peptidergic vasodilator nerves in the peripheral circulation and in the 640 
vascular beds of the heart and brain. Blood Vessels 27 73-93. 641 
57. Oliet SH & Bonfardin VD 2010 Morphological plasticity of the rat supraoptic 642 
nucleus--cellular consequences. European Journal of Neuroscience 32 1989-1994. 643 
58. Dhar M, Wayman GA, Zhu M, Lambert TJ, Davare MA & Appleyard SM 2014 644 
Leptin-induced spine formation requires TrpC channels and the CaM kinase cascade 645 
in the hippocampus. Journal of Neuroscience 34 10022-10033. 646 
59. Dhar M, Zhu M, Impey S, Lambert TJ, Bland T, Karatsoreos IN, Nakazawa T, 647 
Appleyard SM & Wayman GA 2014, Leptin induces hippocampal synaptogenesis via 648 
CREB-regulated microRNA-132 suppression of p250GAP. Molecular Endocrinology 649 
28 1073-1087. 650 
60. Garcia I, Quast KB, Huang L, Herman AM, Selever J, Deussing JM, Justice NJ & 651 
Arenkiel BR 2014 Local CRH signaling promotes synaptogenesis and circuit 652 
integration of adult-born neurons. Developmental Cell 30 645-659. 653 
61. Herman JP & Tasker JG 2016 Paraventricular Hypothalamic Mechanisms of Chronic 654 
Stress Adaptation. Front Endocrinol (Lausanne) 7: 137. 655 
62. Grattan DR 2015 60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-656 
prolactin axis. Journal of Endocrinology 226 T101-122. 657 
63. Russell JA, Leng G & Douglas AJ 2003 The magnocellular oxytocin system, the 658 
fount of maternity: adaptations in pregnancy. Frontiers in Neuroendocrinology 24 27-659 
61. 660 
64. Arrowsmith S & Wray S 2014 Oxytocin: its mechanism of action and receptor 661 
signalling in the myometrium. Journal of Neuroendocrinology 26 356-369. 662 
65. Leng G & Sabatier N 2016 Measuring oxytocin and vasopressin: bioassays, 663 
immunoassays and random numbers. Journal of Neuroendocrinology 28(10). 664 
66. Johnson ZV, Walum H, Xiao Y, Riefkohl PC, & Young LJ 2017 Oxytocin receptors 665 
modulate a social salience neural network in male prairie voles. Hormones and 666 
Behavior 87 16-24. 667 
67. Johnson ZV & Young LJ 2017 Oxytocin and vasopressin neural networks: 668 
Implications for social behavioral diversity and translational neuroscience. Neurosci 669 
Biobehav Rev, 76 87-98. 670 
68. Bicknell RJ 1988 Optimizing release from peptide hormone secretory nerve terminals. 671 
Journal of Experimental Biology 139 51-65. 672 
69. MacGregor DJ & Leng G 2013 Spike triggered hormone secretion in vasopressin 673 
cells; a model investigation of mechanism and heterogeneous population function. 674 
PLoS Computational Biology 9(8): p. e1003187. 675 
70. Higuchi T, Bicknell RJ & Leng G 1991 Reduced oxytocin release from the neural 676 
lobe of lactating rats is associated with reduced pituitary content and does not reflect 677 
reduced excitability of oxytocin neurons. Journal of Neuroendocrinology 3 297-302. 678 
71. Kalwat MA & Cobb MH 2017 Mechanisms of the amplifying pathway of insulin 679 
secretion in the beta cell. Pharmacol Ther, 179 17-30. 680 
72. Seino S, Takahashi H, Fujimoto W & Shibasaki T 2009 Roles of cAMP signalling in 681 
insulin granule exocytosis. Diabetes Obesity and Metabolism 11 Suppl 4 180-188. 682 
73. Brown CH & Bourque CW 2006 Mechanisms of rhythmogenesis: insights from 683 
hypothalamic vasopressin neurons. Trends in Neuroscience 29 108-15. 684 
74. Leng G, Brown C, Sabatier N & Scott V 2008, Population dynamics in vasopressin 685 
cells. Neuroendocrinology 88 160-172. 686 
75. Tobin VA, Arechaga G, Brunton PJ, Russell JA, Leng G, Ludwig M & Douglas AJ 687 
2014 Oxytocinase in the female rat hypothalamus: a novel mechanism controlling 688 
oxytocin neurones during lactation. Journal of Neuroendocrinology 26 205-216. 689 
76. Diao F, Elliott AD, Diao F, Shah S, & White BH 2017 Neuromodulatory connectivity 690 
defines the structure of a behavioral neural network. Elife  6. pii: e29797 691 
77. Bargmann CI 2012 Beyond the connectome: how neuromodulators shape neural 692 
circuits. Bioessays 34 458-465. 693 
78. Elphick MR, Mirabeau O & Larhammar D 2018 Evolution of neuropeptide signalling 694 
systems. Journal of Experimental Biology. 221(Pt 3). 695 
79. Jekely G, Melzer S, Beets I, Kadow ICG, Koene J, Haddad S & Holden-Dye L 2018 696 
The long and the short of it - a perspective on peptidergic regulation of circuits and 697 
behaviour. Journal of Experimental Biology 221(Pt 3). 698 
80. Tessmar-Raible K, Raible F, Christodoulou F, Guy K, Rembold M, Hausen H & 699 
Arendt D 2007 Conserved sensory-neurosecretory cell types in annelid and fish 700 
forebrain: insights into hypothalamus evolution. Cell 129 1389-1400. 701 
81. Tang SC, Baeyens L, Shen CN, Peng SJ, Chien HJ, Scheel DW, Chamberlain CE & 702 
German MS 2018 Human pancreatic neuro-insular network in health and fatty 703 
infiltration. Diabetologia. 61 168-181. 704 
82. Holz GG, Chepurny OG & Leech CA 2013 Leptin-stimulated KATP channel 705 
trafficking: a new paradigm for beta-cell stimulus-secretion coupling? Islets 5 229-706 
232. 707 
83. Kiehn JT, Tsang AH, Heyde I, Leinweber B, Kolbe I, Leliavski A & Oster H 2017 708 
Circadian rhythms in adipose tissue physiology. Comprehensive Physiology 7 383-709 
427. 710 
84. Abu Bakar H, Robert Dunn W, Daly C & Ralevic V 2017 Sensory innervation of 711 
perivascular adipose tissue: a crucial role in artery vasodilatation and leptin release. 712 
Cardiovascular Research 113 962-972. 713 
85. Caron A, Lee S, Elmquist JK & Gautron L 2018 Leptin and brain-adipose crosstalks. 714 
Nature Reviews Neuroscience 19 153-165. 715 
86. Pan W, Adams JM, Allison MB, Patterson C, Flak JN, Jones J, Strohbehn G, 716 
Trevaskis J, Rhodes CJ, Olson DP & Myers MG 2018 Essential role for hypothalamic 717 
calcitonin receptor-expressing neurons in the control of food intake by leptin. 718 
Endocrinology 159 1860-1872. 719 
87. Leinninger GM, Opland DM, Jo YH, Faouzi M, Christensen L, Cappellucci LA, 720 
Rhodes CJ, Gnegy ME, Becker JB, Potho EN et al. 2011 Leptin action via 721 
neurotensin neurons controls orexin, the mesolimbic dopamine system and energy 722 
balance. Cell Metabolism 14 313-323. 723 
88. Pandit R, Beerens S, & Adan RAH, Role of leptin in energy expenditure: the 724 
hypothalamic perspective. American Journal of Physiology 2017. 312 R938-R947. 725 
89. Xu L 2014 Leptin action in the midbrain: From reward to stress. Journal of Chemical 726 
Neuroanatomy 61-62 256-265. 727 
90. Domingos AI, Vaynshteyn J, Voss HU, Ren X, Gradinaru V, Zang F, Deisseroth K, 728 
de Araujo IE & Friedman J 2011 Leptin regulates the reward value of nutrient. Nature 729 
Neuroscience 14 1562-8. 730 
91. McClintock B 1984 The significance of responses of the genome to challenge. 731 
Science 226 792-801. 732 
92. Al-Hasani R, Wong JT, Mabrouk OS, McCall JG, Schmitz GP, Porter-Stransky KA, 733 
Aragona BJ, Kennedy RT & Bruchas MR 2018 In vivo detection of optically-evoked 734 
opioid peptide release. Elife 7. 735 
93. Sun F, Zeng J, Jing M, Zhou J, Feng J, Owen SF, Luo Y, Li F, Wang H, Yamaguchi 736 
T et al. 2018 A genetically encoded fluorescent sensor enables rapid and specific 737 
detection of dopamine in flies, fish, and mice. Cell 174 481-496 e19. 738 
94. Jing M, Zhang P, Wang G, Feng J, Mesik L, Zeng J, Jiang H, Wang S, Looby JC, 739 
Guagliardo NA et al. 2018 A genetically encoded fluorescent acetylcholine indicator 740 
for in vitro and in vivo studies. Nature Biotechnology 36 726-737. 741 
95. Wang H, Jing M & Li Y 2018 Lighting up the brain: genetically encoded fluorescent 742 
sensors for imaging neurotransmitters and neuromodulators. Current Opinion in 743 
Neurobiology 50 171-178. 744 
96. Bendesky A, Kwon YM, Lassance JM, Lewarch CL, Yao S, Peterson BK, He MX, 745 
Dulac C & Hoekstra HE 2017 The genetic basis of parental care evolution in 746 
monogamous mice. Nature 544 434-439. 747 
97. Jiang J, Cui H & Rahmouni K 2017 Optogenetics and pharmacogenetics: principles 748 
and applications. American Journal of Physiology 313 R633-R645. 749 
